Carmell Cash Per Share from 2010 to 2024

CTCX Stock   0.30  0.02  7.14%   
Carmell Therapeutics Cash Per Share yearly trend continues to be fairly stable with very little volatility. Cash Per Share is likely to outpace its year average in 2024. During the period from 2010 to 2024, Carmell Therapeutics Cash Per Share regression line of annual values had r-squared of  0.36 and arithmetic mean of  0.04. View All Fundamentals
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
0.26426067
Current Value
0.28
Quarterly Volatility
0.09543302
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Carmell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Carmell Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 162.5 K or Interest Expense of 844.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.78. Carmell financial statements analysis is a perfect complement when working with Carmell Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Carmell Therapeutics Correlation against competitors.
For more information on how to buy Carmell Stock please use our How to Invest in Carmell Therapeutics guide.

Latest Carmell Therapeutics' Cash Per Share Growth Pattern

Below is the plot of the Cash Per Share of Carmell Therapeutics over the last few years. It is Carmell Therapeutics' Cash Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Carmell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.00 X10 Years Trend
Slightly volatile
   Cash Per Share   
       Timeline  

Carmell Cash Per Share Regression Statistics

Arithmetic Mean0.04
Geometric Mean0
Coefficient Of Variation256.43
Mean Deviation0.06
Median0.0006
Standard Deviation0.1
Sample Variance0.01
Range0.2794
R-Value0.60
Mean Square Error0.01
R-Squared0.36
Significance0.02
Slope0.01
Total Sum of Squares0.13

Carmell Cash Per Share History

2024 0.28
2023 0.26
2022 0.006482

About Carmell Therapeutics Financial Statements

Carmell Therapeutics investors use historical fundamental indicators, such as Carmell Therapeutics' Cash Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Carmell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Per Share 0.26  0.28 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Carmell Stock Analysis

When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.